# vTv Therapeutics Discusses Hypoglycemia in Type 1 Diabetes

> vTv Therapeutics reveals hypoglycemia burden in type 1 diabetes and cadisegliatin phase 3 progress.
- Title: vTv Therapeutics Discusses Hypoglycemia in Type 1 Diabetes
- Summary: vTv Therapeutics reveals hypoglycemia burden in type 1 diabetes and cadisegliatin phase 3 progress. vTv Therapeutics discussed hypoglycemia challenges in…
- Keywords: vtv therapeutics, type 1 diabetes, hypoglycemia, cadisegliatin, phase 3 program, investor event, money, business, vTv, Therapeutics, Discusses, Type
- Source: Seekingalpha — https://seekingalpha.com/article/4956086-vtv-therapeutics-inc-vtvt-discusses-hypoglycemia-burden-in-type-1-diabetes-and-cadisegliatin
- Author: SA Transcripts
- Published: 2026-10-21T22:03:05+00:00
- Read time: 1 min
- Topics: vtv therapeutics, type 1 diabetes, hypoglycemia, cadisegliatin, phase 3 program, investor event, money, business
## vTv Therapeutics
vTv Therapeutics Inc. published a slide deck discussing hypoglycemia burden in type 1 diabetes and cadisegliatin phase 3 program.
## Investor Event
The slide deck was created for an investor event and published by vTv Therapeutics Inc. on Seeking Alpha.
## Cadisegliatin Phase 3
vTv Therapeutics is advancing cadisegliatin through phase 3 clinical trials for type 1 diabetes treatment.
## Key takeaway

vTv Therapeutics discussed hypoglycemia challenges in type 1 diabetes and cadisegliatin phase 3 program during investor event.